GlycoNex Enters Clinical Stage with Novel Cancer-Fighting ADC

NEW TAIPEI CITY, Taiwan – April 14, 2026 – Taiwanese biotechnology firm GlycoNex, Inc. has received a crucial green light from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to begin a first-in-human clinical trial for its lead drug candidate, GNX1021. The approval marks a pivotal moment for the company, transitioning it to a clinical-stage entity and launching a potentially new front in the war against advanced gastrointestinal cancers.

The Phase 1 trial will evaluate GNX1021, a sophisticated antibody-drug conjugate (ADC), in patients with hard-to-treat gastric, pancreatic, and colorectal cancers. This milestone not only validates GlycoNex's proprietary technology platform but also shines a spotlight on an innovative strategy that targets cancer's unique sugar coating, a departure from many conventional targeted therapies.

A Novel Attack on Cancer's Sugar Coating

At the heart of GNX1021's design is a fundamentally different approach to finding and destroying cancer cells. Unlike many precision oncology drugs that target a single, specific protein on a tumor's surface, GNX1021 targets glycans—complex carbohydrate structures that are abnormally overexpressed on cancer cells. This forms a "sugar shield" that is a hallmark of many malignancies.

Specifically, the drug is engineered to seek out an antigen known as bLeB/Y, a branched glycan structure found in high concentrations on epithelial tumors but minimally on healthy tissues. This high specificity is the cornerstone of its design, aiming to create a wider therapeutic window and enhance patient safety by leaving healthy cells unharmed.

This glycan-targeting mechanism offers a powerful solution to one of modern oncology's biggest hurdles: tumor heterogeneity. Within a single tumor, cancer cells can be vastly different, with some expressing a target protein while others do not. This diversity allows resistant cells to survive treatment and drive disease progression. By targeting a glycan structure present across multiple different cancer-associated proteins, GNX1021 can engage with a broader array of malignant cells, potentially preventing escape and improving treatment efficacy.

"GNX1021 represents a differentiated approach to ADC development, designed to address tumor heterogeneity by targeting glycan structures broadly expressed across multiple cancer-associated proteins," said Dr. Mei-Chun Yang, Chief Executive Officer of GlycoNex, in a statement. "We believe this unique mechanism... positions GNX1021 to potentially deliver meaningful clinical benefit."

Preclinical toxicology studies in rats and cynomolgus monkeys have already bolstered confidence in the drug's safety, demonstrating a stable metabolic process without significant damage to major organs. This robust preclinical data was instrumental in securing the PMDA's approval to proceed with human trials.

Addressing a Critical Unmet Need in GI Cancers

The initiation of the GNX1021 trial brings a new glimmer of hope for patients battling advanced gastrointestinal (GI) cancers, a group of diseases notorious for their aggressive nature and poor prognoses. Gastric, pancreatic, and colorectal cancers are leading causes of cancer-related death worldwide, often because they are diagnosed at late stages when the disease has already spread.

For these patients, treatment options can be limited. While targeted therapies like Enhertu, which targets the HER2 protein, have transformed outcomes for a subset of patients, many do not have tumors that express these specific markers. For instance, the bLeB/Y antigen targeted by GlycoNex's drug is estimated to be highly prevalent in 50% to 60% of gastric tumors, a significantly larger population than the less than 10% eligible for certain HER2-targeted treatments in some cohorts.

GNX1021 aims to fill this gap, offering a potential new therapeutic avenue for a broader patient population that has exhausted standard-of-care chemotherapy and is ineligible for other targeted agents. The multi-center, multinational Phase 1 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the drug, with the ultimate goal of establishing a safe and effective dose for further studies.

From Local Biotech to Global Clinical Player

This regulatory approval is more than just a scientific step forward; it represents a major strategic leap for GlycoNex. The move into clinical trials in Japan, a key global pharmaceutical market, elevates the New Taipei City-based company's status and validates its decade-long focus on glycan-directed immunotherapies.

Patient enrollment in Japan is slated to begin in June 2026. The company also plans to file an Investigational New Drug (IND) application in its home market of Taiwan in June, with patient enrollment there anticipated to start in the third quarter of 2026. This dual-country approach underscores a strategy aimed at gathering diverse data and accelerating the drug's development pathway.

"PMDA approval to initiate our first-in-human study is a defining milestone for GlycoNex and a critical validation of our glycan-targeting platform," Dr. Yang stated, emphasizing the significance of the achievement for the company's trajectory.

The advancement comes at a time when the ADC market is red-hot, with major pharmaceutical companies paying billions for promising new assets. By successfully advancing a candidate with a unique target into the clinic, GlycoNex is positioning itself as an attractive partner. Dr. Yang noted the intense global interest in novel ADCs, pointing out that drugs with unique targets reaching Phase 1 can command total deal values from several hundred million to over a billion dollars. This potential for a lucrative partnership could provide the capital needed to fund GNX1021 through later-stage trials and expand the company's pipeline, which also includes a monoclonal antibody, GNX102, that has already completed Phase 1 trials. While the company's stock (4168 on the Taiwan exchange) has seen a decline in recent months, this clinical progress could serve as a significant catalyst for renewed investor confidence.

As GlycoNex prepares to dose its first patient, the oncology community will be watching closely. The trial's success could not only pave the way for a new treatment for devastating cancers but also validate the immense potential of targeting cancer's complex sugar shield.